Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours

@article{Jones2019MolecularCA,
  title={Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours},
  author={David T. W. Jones and Ana Banito and Thomas G. P. Gr{\"u}newald and Michelle Haber and Natalie J{\"a}ger and Marcel Kool and Till Milde and Jan J. Molenaar and Arash Nabbi and Trevor J. Pugh and Gudrun Schleiermacher and Malcolm A. Smith and Frank Westermann and Stefan M. Pfister},
  journal={Nature Reviews Cancer},
  year={2019},
  pages={1-19}
}
The spectrum of tumours arising in childhood is fundamentally different from that seen in adults, and they are known to be divergent from adult malignancies in terms of cellular origins, epidemiology, genetic complexity, driver mutations and underlying mutational processes. Despite the immense knowledge generated through sequencing efforts and functional characterization of identified (epi-)genetic alterations over the past decade, the clinical implications of this knowledge have so far been… 
Molecular targeting therapies for neuroblastoma: Progress and challenges
TLDR
This review provides a comprehensive overview of the molecular targeted therapies under preclinical and clinical investigations, particularly those targeting ALK signaling, MDM2, PI3K/Akt/mTOR and RAS‐MAPK pathways, as well as epigenetic regulators, and gives insights on the use of combination therapies involving novel agents that target various pathways.
[Integrative molecular pathology of cancer].
TLDR
Investigations in the Ewing sarcoma model demonstrate that the function of a driver mutation needs to be interpreted in its germline context, which should be taken into account in an integrative approach by the molecular pathology of the future.
International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
TLDR
Recommendations based on the experience of the NCI funded PPTP/C and the EU funded ITCC-P4 public private partnership can serve as a minimal guidance necessary to jumpstart preclinical pediatric research globally.
Liquid Biomarkers for Pediatric Brain Tumors: Biological Features, Advantages and Perspectives
TLDR
Current knowledge on liquid biopsy markers and technologies in pediatric brain tumors, their advantages and drawbacks, as well as future potential biomarkers and perspectives with respect to clinical implementation in patient care are summarized.
Preclinical In Vivo Modeling of Pediatric Sarcoma—Promises and Limitations
TLDR
This review of available approaches to model sarcoma in vivo focused on genetically engineered and patient-derived mouse models, compared strengths and weaknesses, and finally explored possibilities and limitations to utilize these models to advance both biological understanding as well as clinical diagnosis and therapy.
From Bench to Bedside, the Current State of Oncolytic Virotherapy in Pediatric Glioma.
TLDR
Several oncolytic viruses are reviewed, with a focus on molecular mechanism and efficacy of these viruses in tumor cell lines and murine models, and current phase I clinical trials evaluating on colytic virotherapy in the treatment of pediatric glioma are summarized.
Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development.
TLDR
Preclinical testing of relevant drugs in pediatric tumor-specific in vitro and in vivo models and international collaboration are required to address the resource constraints and increasing number of potential products to be tested in a timely, efficient, nonduplicative, and cost-effective manner.
...
...

References

SHOWING 1-10 OF 263 REFERENCES
The landscape of genomic alterations across childhood cancers
TLDR
The data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective
TLDR
The strategy of the Innovative Therapies for Children with Cancer (ITCC) Consortium is described, which advocates for the adoption of trial designs that enable uninterrupted patient recruitment, the extrapolation from studies in adults when possible, and the inclusion of expansion cohorts.
The whole-genome landscape of medulloblastoma subtypes
TLDR
The application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma.
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.
TLDR
In this single-center case series involving young patients with relapsed or refractory cancer, incorporation of integrative clinical sequencing data into clinical management was feasible, revealed potentially actionable findings in 46% of patients, and was associated with change in treatment and family genetic counseling for a small proportion of patients.
Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies
TLDR
The biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors is discussed.
Therapeutic Targeting of Ependymoma as Informed by Oncogenic Enhancer Profiling
TLDR
Through profiling of transcriptional enhancers, this study provides a framework for target and drug discovery in other cancers that lack known genetic drivers and are therefore difficult to treat, and reveals putative oncogenes, molecular targets and pathways.
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma
TLDR
These new genetic findings give insights into disease pathogenesis and the challenges and opportunities for improving patient survival in these mostly incurable childhood brain tumours.
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
TLDR
The hallmark genetic alterations that are associated with distinct epigenetic features and patient characteristics in both paediatric and adult disease are summarized, and the complex interplay between the glioblastoma genome and epigenome is examined.
Family-based germline sequencing in children with cancer
TLDR
Family-based trio sequencing has the potential to reveal a striking new landscape of inheritance in childhood cancer and to facilitate the integration and efforts of individualized treatment strategies, including personalized and preventive medicine and cancer surveillance programs.
...
...